Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 4/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ESRRA | P11474 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21863517 | 0.76 | ALDH1A1 (0.41) | MGLLALDH1A1NOTUM | |
| SCHEMBL28600542 | 0.75 | P2RX7 (0.38) | MGLLNOTUMPOLBTDP1 | |
| SCHEMBL29450896 | 0.73 | MAPK14 (0.50) | MYCMAPK14ALDH1A1ALOX15NR4A1 | |
| SCHEMBL21849198 | 0.73 | TRPV1 (0.43) | NOTUM | |
| SCHEMBL29451047 | 0.72 | LDHA (0.57) | MAPK14MAPT | |
| SCHEMBL30271725 | 0.71 | F11 (0.50) | NOTUM | |
| SCHEMBL21816247 | 0.71 | MYC (0.46) | MYCMGLLALDH1A1ALOX15TAS2R14 | |
| SCHEMBL6422176 | 0.71 | MYC (0.46) | MYCALDH1A1ALOX15NR4A1POLB | |
| SCHEMBL21816258 | 0.71 | MYC (0.46) | MYCALDH1A1ALOX15TAS2R14NR4A1 | |
| SCHEMBL15714398 | 0.68 | MYC (0.79) | MYCALDH1A1ALOX15NOTUMNR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-11597728-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-07 | — | — | US | disclosed |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
| EP-3856179-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2021-08-04 | — | — | EP | disclosed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020065614-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020065614-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MYC 4570/4885MAPK14 4211/4885MGLL 1/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | MYC 4570/4885MAPK14 4211/4885MGLL 1/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MYC 4570/4885MAPK14 4211/4885MGLL 1/4885 |
| US-11597728-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | MYC 4570/4885MAPK14 4211/4885MGLL 1/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MYC 4570/4885MAPK14 4211/4885MGLL 1/4885 |
| US-20220315583-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MYC 4570/4885MAPK14 4211/4885MGLL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.